| Literature DB >> 33408779 |
Wenhao Mao1, Jia Mai2, Hui Peng1, Junhu Wan1, Ting Sun1.
Abstract
Pancreatic cancer, especially pancreatic ductal adenocarcinoma (PDAC), remains a fatal disease with few efficacious treatments. The Hippo signaling pathway, an evolutionarily conserved signaling module, plays critical roles in tissue homeostasis, organ size control and tumorigenesis. The transcriptional coactivator yes-associated protein (YAP), a major downstream effector of the Hippo pathway, is associated with various human cancers including PDAC. Considering its importance in cancer, YAP is emerging as a promising therapeutic target. In this review, we summarize the current understanding of the oncogenic role and regulatory mechanism of YAP in PDAC, and the potential therapeutic strategies targeting YAP. © The author(s).Entities:
Keywords: Hippo pathway; KRAS; Pancreatic cancer; YAP; therapeutic target
Year: 2021 PMID: 33408779 PMCID: PMC7778590 DOI: 10.7150/thno.53438
Source DB: PubMed Journal: Theranostics ISSN: 1838-7640 Impact factor: 11.556